Clinical and Molecular Hepatology

"Gi Hong Choi"

Original Articles

Liver Transplantation

Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma: Incheon Kang, Jae Geun Lee, Sung Hoon Choi, Hyun Jeong Kim, Dai Hoon Han, Gi Hong Choi, Myoung Soo Kim, Jin Sub Choi, Soon Il Kim, Dong Jin Joo; Clin Mol Hepatol 2021;27(4):589-602.
Published online July 23, 2021; DOI: https://doi.org/10.3350/cmh.2021.0038

Background/Aims
This study aimed to investigate whether everolimus (EVR) affects long-term survival after liver transplantation (LT) in patients with hepatocellular carcinoma (HCC).
Methods
The data from 303 consecutive patients with HCC who had undergone LT from January 2012 to July 2018 were retrospectively reviewed. The patients were divided into two groups: 1) patients treated with EVR in combination with calcineurin inhibitors (CNIs) (EVR group; n=114) and 2) patients treated with CNI-based therapy without EVR (non-EVR group; n=189). Time to recurrence (TTR) and overall survival (OS) after propensity score (PS) matching were compared between the groups, and prognostic factors for TTR and OS were evaluated.
Results
The EVR group exhibited more aggressive tumor biology than the non-EVR group, such as a higher number of tumors (P=0.003), a higher prevalence of microscopic vascular invasion (P=0.017) and exceeding Milan criteria (P=0.029). Compared with the PS-matched non-EVR group, the PS-matched EVR group had significantly better TTR (P<0.001) and OS (P<0.001). In multivariable analysis, EVR was identified as an independent prognostic factor for TTR (hazard ratio [HR], 0.248; P=0.001) and OS (HR, 0.145; P<0.001).
Conclusions
Combined with CNIs, EVR has the potential to prolong long-term survival in patients undergoing LT for HCC. These findings warrant further investigation in a well-designed prospective study.

Citations

Citations to this article as recorded by

Everolimus Personalized Therapy: Second Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Satohiro Masuda, Florian Lemaitre, Markus J. Barten, Stein Bergan, Maria Shipkova, Teun van Gelder, Sander Vinks, Eberhard Wieland, Kirsten Bornemann-Kolatzki, Mercè Brunet, Brenda de Winter, Maja-Theresa Dieterlen, Laure Elens, Taihei Ito, Kamisha Johnso
Therapeutic Drug Monitoring.2025; 47(1): 4. CrossRef
Genetic alterations are related to clinicopathological features and risk of recurrence/metastasis of hepatocellular carcinoma
Lili Meng, Zhenjian Jiang, Guangyue Shen, Shulan Lin, Feng Gao, Xinxin Guo, Bin Lv, Shuying Hu, Zheng Ni, Shanghua Chen, Yuan Ji
European Journal of Cancer Prevention.2025; 34(5): 456. CrossRef
Association between everolimus combination therapy and cancer risk after liver transplantation: A nationwide population-based quasi-cohort study
Suk-Chan Jang, Gi-Ae Kim, Young-Suk Lim, Hye-Lin Kim, Eui-Kyung Lee
American Journal of Transplantation.2025; 25(6): 1285. CrossRef
Adjuvant chemotherapy improves post-transplant outcome in patients with hepatocellular carcinoma
Heng-Kai Zhu, Hai-Bo Mou, Zhuo-Yi Wang, Wu Zhang, Dan Zhu, Si-Yi Zhong, Shu-Sen Zheng, Li Zhuang
Hepatobiliary & Pancreatic Diseases International.2025; 24(5): 491. CrossRef
Optimizing patient selection and immunosuppression in improving long-term survival after living donor liver transplantation for hepatocellular carcinoma
JaRyung Han, Young Seok Han
Annals of Liver Transplantation.2025; 5(1): 1. CrossRef
Cellular Cancer Immunotherapy in the Liver Transplant Population for HCC: An Attractive Therapeutic Option for the Next Decade
Dongdong Yu, Shuchan Li, Hao Chen, Lidong Wang
Clinical Transplantation.2025;[Epub] CrossRef
Toward optimized immunosuppression balance in liver transplantation: Clinical insights from lower tacrolimus exposure
Sung-Min Kim
Annals of Liver Transplantation.2025; 5(2): 65. CrossRef
High Number of Plasma Exchanges Increases the Risk of Bacterial Infection in ABO-incompatible Living Donor Liver Transplantation
Mun Chae Choi, Eun-Ki Min, Seung Hyuk Yim, Deok-Gie Kim, Jae Geun Lee, Dong Jin Joo, Myoung Soo Kim
Transplantation.2024; 108(8): 1760. CrossRef
Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation
Dong-Sik Kim, Young-In Yoon, Beom Kyung Kim, Ashok Choudhury, Anand Kulkarni, Jun Yong Park, Jongman Kim, Dong Hyun Sinn, Dong Jin Joo, YoungRok Choi, Jeong-Hoon Lee, Ho Joong Choi, Ki Tae Yoon, Sun Young Yim, Cheon-Soo Park, Deok-Gie Kim, Hae Won Lee, Wo
Hepatology International.2024; 18(2): 299. CrossRef
Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation
Paolo De Simone, Arianna Precisi, Quirino Lai, Juri Ducci, Daniela Campani, Piero Marchetti, Stefano Gitto
Cancers.2024; 16(7): 1243. CrossRef
Liver Transplantation for Hepatocarcinoma: Results over Two Decades of a Transplantation Programme and Analysis of Factors Associated with Recurrence
María Martínez Burgos, Rocío González Grande, Susana López Ortega, Inmaculada Santaella Leiva, Jesús de la Cruz Lombardo, Julio Santoyo Santoyo, Miguel Jiménez Pérez
Biomedicines.2024; 12(6): 1302. CrossRef
Hepatocellular carcinoma recurrence after liver transplantation: risk factors, targeted surveillance and management options
Filippo Pelizzaro, Alberto Ferrarese, Martina Gambato, Alberto Zanetto, Francesco Paolo Russo, Giacomo Germani, Marco Senzolo, Mario Domenico Rizzato, Caterina Soldà, Alessandro Vitale, Enrico Gringeri, Umberto Cillo, Patrizia Burra
Hepatoma Research.2024;[Epub] CrossRef
Sirolimus improves the prognosis of liver recipients with hepatocellular carcinoma: A single-center experience
Peng Liu, Xin Wang, Huan Liu, Shu-Xian Wang, Qing-Guo Xu, Lin Wang, Xiao Xu, Jin-Zhen Cai
Hepatobiliary & Pancreatic Diseases International.2023; 22(1): 34. CrossRef
Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management
Sara Battistella, Francesca D’Arcangelo, Marco Grasso, Alberto Zanetto, Martina Gambato, Giacomo Germani, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra
Clinical and Molecular Hepatology.2023; 29(Suppl): S286. CrossRef
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Journal of Liver Cancer.2023; 23(1): 1. CrossRef
Immunosuppressive Medication Adherence in Patients With Hepatocellular Cancer Who Have Undergo Liver Transplantation: A Case Control Study
Sami Akbulut, Murat Tamer, Serdar Saritas, Ozlem Unal, Musap Akyuz, Selver Unsal, Zeynep Kucukakcali, Ertugrul Karabulut, Sertac Usta, Sezai Yilmaz
Transplantation Proceedings.2023; 55(5): 1231. CrossRef
Risk factors for late-onset Pneumocystis jirovecii pneumonia in liver transplant recipients
Eun-Ki Min, Juhan Lee, Su Jin Jeong, Deok-Gie Kim, Seung Hyuk Yim, Mun Chae Choi, Dong Jin Joo, Myoung Soo Kim, Jae Geun Lee
International Journal of Infectious Diseases.2023; 131: 166. CrossRef
Metronomic capecitabine with rapamycin exerts an immunosuppressive effect by inducing ferroptosis of CD4+ T cells after liver transplantation in rat
Hao Wang, Ruining Yang, Zhenglu Wang, Lei Cao, Dejun Kong, Qian Sun, Sei Yoshida, Jiashu Ren, Tao Chen, Jinliang Duan, Jianing Lu, Zhongyang Shen, Hong Zheng
International Immunopharmacology.2023; 124: 110810. CrossRef
Association between the early high level of serum tacrolimus and recurrence of hepatocellular carcinoma in ABO-incompatible liver transplantation
Ji Won Han, Jong Young Choi, Eun Sun Jung, Ji Hoon Kim, Hee Sun Cho, Jae-Sung Yoo, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Ho Joong Choi, Young Kyoung You
World Journal of Gastrointestinal Surgery.2023; 15(12): 2727. CrossRef
Safety of Tacrolimus Monotherapy within 12 Months after Liver Transplantation in the Era of Reduced Tacrolimus and Mycophenolate Mofetil: National Registry Study
Deok Gie Kim, Sung Hwa Kim, Shin Hwang, Suk Kyun Hong, Je Ho Ryu, Bong-Wan Kim, Young Kyoung You, Donglak Choi, Dong-Sik Kim, Yang Won Nah, Jai Young Cho, Tae-Seok Kim, Geun Hong, Dong Jin Joo, Myoung Soo Kim, Jong Man Kim, Jae Geun Lee
Journal of Clinical Medicine.2022; 11(10): 2806. CrossRef
2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

Korean Journal of Radiology.2022; 23(12): 1126. CrossRef
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Clinical and Molecular Hepatology.2022; 28(4): 583. CrossRef
Clinical association between tacrolimus intra-patient variability and liver transplantation outcomes in patients with and without hepatocellular carcinoma
Hyun Jeong Kim, Juhan Lee, Jae Geun Lee, Dong Jin Joo, Myoung Soo Kim
Scientific Reports.2022;[Epub] CrossRef
The first successful report of liver transplantation from category III donation after circulatory death in South Korea: a case report
Incheon Kang, Jae-myeong Lee, Jae Geun Lee
Korean Journal of Transplantation.2022; 36(4): 294. CrossRef
Can hepatocellular carcinoma recurrence be prevented after liver transplantation?
Jong Man Kim
Clinical and Molecular Hepatology.2021; 27(4): 562. CrossRef
Human Cytomegalovirus Is Associated with Lower HCC Recurrence in Liver Transplant Patients
Po-Jung Hsu, Hao-Chien Hung, Jin-Chiao Lee, Yu-Chao Wang, Chih-Hsien Cheng, Tsung-Han Wu, Ting-Jung Wu, Hong-Shiue Chou, Kun-Ming Chan, Wei-Chen Lee, Chen-Fang Lee
Current Oncology.2021; 28(6): 4281. CrossRef
Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma
Soon Kyu Lee, Sung Won Lee, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon
International Journal of Molecular Sciences.2021; 22(19): 10271. CrossRef
Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation
Filippo Pelizzaro, Martina Gambato, Enrico Gringeri, Alessandro Vitale, Umberto Cillo, Fabio Farinati, Patrizia Burra, Francesco Paolo Russo
Cancers.2021; 13(19): 4882. CrossRef

11,677 View
265 Download
27 Web of Science
Crossref

Hepatic neoplasm

Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein level predicts recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection: Hye Soo Kim, Seung Up Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Young Nyun Park, Dai Hoon Han, Kyung Sik Kim, Jin Sub Choi, Gi Hong Choi, Hyon-Suk Kim; Clin Mol Hepatol 2020;26(1):33-44.
Published online June 27, 2019; DOI: https://doi.org/10.3350/cmh.2018.0073

Background/Aims
To investigate whether serum Wisteria floribunda agglutinin-positive human Mac-2-binding protein (WFA⁺-M2BP) can predict the recurrence of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) after curative resection.
Methods
Patients with chronic hepatitis B (CHB) who underwent curative resection for HCC between 2004 and 2015 were eligible for the study. Recurrence was sub-classified as early (<2 years) or late (≥2 years).
Results
A total of 170 patients with CHB were selected. During the follow-up period (median, 22.6 months), 64 (37.6%) patients developed recurrence. In multivariate analyses, WFA⁺-M2BP level was an independent predictor of overall (hazard ratio [HR]=1.490), early (HR=1.667), and late recurrence (HR=1.416), together with male sex, des-gamma carboxyprothrombin level, maximal tumor size, portal vein invasion, and satellite nodules (all P<0.05). However, WFA⁺- M2BP level was not predictive of grade B-C posthepatectomy liver failure. The cutoff value that maximized the sum of sensitivity (30.2%) and specificity (90.6%) was 2.14 (area under receiver operating characteristic curve=0.632, P=0.010). Patients with a WFA⁺-M2BP level >2.14 experienced recurrence more frequently than those with a WFA⁺-M2BP level ≤2.14 (P=0.011 by log-rank test), and had poorer postoperative outcomes than those with a WFA⁺-M2BP level ≤2.14 in terms of overall recurrence (56.0 vs. 34.5%, P=0.047) and early recurrence (52.0 vs. 20.7%, P=0.001).
Conclusions
WFA⁺-M2BP level is an independent predictive factor of HBV-related HCC recurrence after curative resection. Further studies should investigate incorporation of WFA⁺-M2BP level into tailored postoperative surveillance strategies for patients with CHB.

Citations

Citations to this article as recorded by

Glycomics as prognostic biomarkers of hepatocellular carcinoma: A systematic review
Nicky Somers, Emma Butaye, Lorenz Grossar, Nele Pauwels, Anja Geerts, Sarah Raevens, Sander Lefere, Lindsey Devisscher, Leander Meuris, Nico Callewaert, Hans Van Vlierberghe, Xavier Verhelst
Oncology Letters.2024;[Epub] CrossRef
Prognostic value of preoperative systemic immune-inflammation index/albumin for patients with hepatocellular carcinoma undergoing curative resection
Kun-Lin Chen, Yi-Wen Qiu, Ming Yang, Tao Wang, Yi Yang, Hai-Zhou Qiu, Ting Sun, Wen-Tao Wang
World Journal of Gastroenterology.2024; 30(48): 5130. CrossRef
Post-operative recurrence of liver cancer according to antiviral therapy for detectable hepatitis B viremia: A nationwide study
Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim
European Journal of Internal Medicine.2023; 107: 66. CrossRef
Comparable Mortality Between Asian Patients with Chronic Hepatitis B Under Long-Term Antiviral Therapy vs Matched Control: A Population-Based Study
Byungyoon Yun, Juyeon Oh, Sang Hoon Ahn, Jin-Ha Yoon, Beom Kyung Kim
American Journal of Gastroenterology.2023; 118(6): 1001. CrossRef
Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis
Daniel Q. Huang, Nobuharu Tamaki, Hyung Woong Lee, Soo Young Park, Yu Rim Lee, Hye Won Lee, Seng Gee Lim, Tae Seop Lim, Masayuki Kurosaki, Hiroyuki Marusawa, Toshie Mashiba, Masahiko Kondo, Yasushi Uchida, Haruhiko Kobashi, Koichiro Furuta, Namiki Izumi,
Hepatology.2023; 77(5): 1746. CrossRef
Perioperative predictors of outcome of hepatectomy for HBV-related hepatocellular carcinoma
Ziming He, Di Tang
Frontiers in Oncology.2023;[Epub] CrossRef
Serum wisteria floribunda agglutinin-positive human Mac-2 binding protein is unsuitable as a diagnostic marker of occult hepatocellular carcinoma in end-stage liver cirrhosis
Kantoku Nagakawa, Masaaki Hidaka, Takanobu Hara, Hajime Matsushima, Hajime Imamura, Takayuki Tanaka, Tomohiko Adachi, Akihiko Soyama, Kengo Kanetaka, Susumu Eguchi, Jincheng Wang
PLOS ONE.2023; 18(11): e0293593. CrossRef
Validation of PH and Varices Risk Scores for Prediction of High-Risk Esophageal Varix and Bleeding in Patients with B-Viral Cirrhosis
Seunghwan Shin, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
Diagnostics.2022; 12(2): 441. CrossRef
Mac-2 binding protein glycosylation isomer (M2BPGi) to evaluate liver fibrosis and cancer in HBV-infected patients in West Africa
Jeanne Perpétue Vincent, Gibril Ndow, Shintaro Ogawa, Amie Ceesay, Ramou Njie, Bakary Sanneh, Ignatius Baldeh, Umberto D’Alessandro, Maimuna Mendy, Mark Thursz, Isabelle Chemin, Yasuhito Tanaka, Maud Lemoine, Yusuke Shimakawa
Journal of Global Health.2022;[Epub] CrossRef
A Mac-2 Binding Protein Glycosylation Isomer-Based Risk Model Predicts Hepatocellular Carcinoma in HBV-Related Cirrhotic Patients on Antiviral Therapy
Chien-Hung Chen, Tsung-Hui Hu, Jing-Houng Wang, Hsueh-Chou Lai, Chao-Hung Hung, Sheng-Nan Lu, Cheng-Yuan Peng
Cancers.2022; 14(20): 5063. CrossRef
External validation of CAGE‐B and SAGE‐B scores for Asian chronic hepatitis B patients with well‐controlled viremia by antivirals
Jung Hyun Ji, Soo Young Park, Won Jeong Son, Hye Jung Shin, Hyein Lee, Hye Won Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
Journal of Viral Hepatitis.2021; 28(6): 951. CrossRef
Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma
Sojung Han, Hye Jin Choi, Seung-Hoon Beom, Hye Rim Kim, Hyein Lee, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Beom Kyung Kim
Journal of Cancer Research and Clinical Oncology.2021; 147(10): 3123. CrossRef
Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B
Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park
Journal of Viral Hepatitis.2021; 28(11): 1570. CrossRef
Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy
Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, Hye Jung Shin, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
Cancers.2021; 13(23): 5892. CrossRef
Usefulness of Mac-2 binding protein glycosylation isomer in non-invasive probing liver disease in the Vietnamese population
Thuy Thi Thu Pham, Dat Tan Ho, Toan Nguyen
World Journal of Hepatology.2020; 12(5): 210. CrossRef
Wisteria floribunda agglutinin-positive Mac-2-binding protein as a diagnostic biomarker in liver cirrhosis: an updated meta-analysis
Shu Feng, Zhonghao Wang, Yanhua Zhao, Chuanmin Tao
Scientific Reports.2020;[Epub] CrossRef
Novel biomarkers for the management of chronic hepatitis B
Takako Inoue, Yasuhito Tanaka
Clinical and Molecular Hepatology.2020; 26(3): 261. CrossRef

9,232 View
203 Download
21 Web of Science
Crossref

Co-expression patterns of Notch1, Snail, and p53 in grade III hepatocellular carcinoma with postoperative recurrence: a preliminary study: Sun Kyung Jang, Gi Hong Choi, Junjeong Choi, Xiaoyuan Quan, Jeong Won Jang, Bo Hyun Kim, Guhung Jung, Young Min Park; Korean J Hepatol 2012;18(1):63-74.
Published online March 22, 2012; DOI: https://doi.org/10.3350/kjhep.2012.18.1.63

Abstract
PDF

Background/Aims

We aimed to determine the association between the co-expression patterns of Notch1, Snail, and p53 proteins (NSP) and the postoperative prognosis of hepatocellular carcinoma (HCC).

Methods

The immunoblot data for molecular expression (147 HCC/corresponding non-HCC tissues and 15 dysplastic nodules) and the sequencing data for p53 mutations (110 HCCs) were obtained from our previous study. Data analyses were restricted to cases with HCC differentiation grade III (n=47), due to its high p53 mutation rate.

Results

Nineteen of the 47 patients (40.4%) -comprising 12 in the liver and 7 in distant organs-had relapsed at 1-2 years after surgery. There was no relationship between p53 mutation and postoperative recurrence in the grade III HCCs. Seven (87.5%) of the eight relapsed cases with Notch1, Snail, and p53 (wild) co-expression experienced recurrence only within the liver, and all tumors were smaller than 5 cm in diameter. Extrahepatic relapse occurred mostly in HCC patients with tumors larger than 5 cm in diameter, without any deviation in the NSP pattern.

Conclusions

The results of this preliminary study suggest that the co-expression of Notch1, Snail, and p53 (wild) is not inferior to the patterns with p53 mutation as an indicator of postoperative recurrence of grade III HCC.

Citations

Citations to this article as recorded by

Hepatocellular carcinoma: Where are we in 2018?
William C. Chapman, Kevin M. Korenblat, Kathryn J. Fowler, Nael Saad, Adeel S. Khan, Vijay Subramanian, Maria B. Majella Doyle, Leigh Anne Dageforde, Benjamin Tan, Patrick Grierson, Yiing Lin, Min Xu, Elizabeth M. Brunt
Current Problems in Surgery.2018; 55(11): 450. CrossRef
High expression of Snail and NF-κB predicts poor survival in Chinese hepatocellular carcinoma patients
Min Zhang, Xin Dong, Dengcai Zhang, Xiaojie Chen, Xinyu Zhu
Oncotarget.2017; 8(3): 4543. CrossRef